Experts say that at some point in their lives, 40 percent of adults in the U.S. will be diagnosed with cancer. The National Cancer Institute estimates that by 2024 there will be over 19 million people in the country with cancer. Tempus, co-founded by Eric Lekofsky, is helping stem that tide by leading the development of data-enabled precision medicine. Lekofsky, the co-founder of Groupon, quickly grew a strong desire to find effective cancer treatment after his wife was diagnosed with breast cancer.
After intensive research, he found that one of the biggest deficiencies in the area of cancer treatment was in data collection and digital technology. With the goal of filling this gap, he helped start Tempus. They immediately went about developing a method to analyze each cancer patients clinical and molecular data to thereby form a precise course of treatment. The fledgling company overcame the early problem of providing accessible and affordable clinical and medical data.
Tempus developed software that makes it easy for doctors to look up the precise details of the cancer patient in their care. All of the available information is constantly updated as the information comes in. In addition, although the technological data of individual patients had technically been around for some time, Tempus made it exceedingly less expense. We are talking about a drop from $100 million to just $5,000. This process, called human genome sequencing, is expected to drop even further in the coming years and more information click here.
Human gene study is widely viewed as being the key to effectively fight cancer so this is where Tempus will stay. Lefkofsky fully anticipates that Tempus will uncover many more cancer-combating secrets in the coming years. But as time goes on Tempus will undoubtedly have more and more competition as more organizations are starting up to do the same thing and learn more about Eric.
More Visit: http://www.lightbank.com/team/eric-lefkofsky